HEAD-TO-HEAD
Semaglutide vs Tirzepatide: Head-to-Head Research
One drug wins the scale, the other owns the outcome trials. Both statements are backed by published numbers.
The short version
Here is semaglutide vs tirzepatide in two lines. On weight, tirzepatide wins the only large head-to-head trial: about 20% lost versus 14% over 72 weeks [1]. On proven outcomes — heart attacks, strokes, kidney failure prevented — semaglutide has the deeper published record [3][5].
Both are once-weekly injections that act on the GLP-1 system. The difference is that tirzepatide also activates a second hormone receptor (GIP), which appears to give it an edge on weight and blood sugar. But "more weight lost" and "more events prevented in a hard-endpoint trial" are different claims, and right now they point at different drugs. This page lays out every comparable figure so you can see the trade clearly. It is a reading of the trial record, not advice, and it names no brands — only the generic compounds.
Weight: SURMOUNT-5, the direct comparison
The cleanest comparison is SURMOUNT-5, a 2025 head-to-head trial that randomized 751 adults with obesity to semaglutide or tirzepatide for 72 weeks. The result: a mean weight change of -20.2% with tirzepatide versus -13.7% with semaglutide — roughly a 6.5 percentage-point advantage for tirzepatide, statistically significant at P<0.001 [1].
That is a direct, randomized comparison, which is the strongest kind of evidence for a head-to-head question. It does not depend on comparing across separate trials with different populations. On the specific endpoint of mean body-weight reduction in adults with obesity, tirzepatide produced the larger number.
Diabetes and blood sugar: SURPASS-2
The pattern repeated in type 2 diabetes a year earlier. In SURPASS-2, the dual GIP/GLP-1 agonist tirzepatide produced greater reductions in both HbA1c (a three-month blood-sugar average) and body weight than once-weekly semaglutide 1.0 mg at 40 weeks [9].
For context on semaglutide's own diabetes performance against an older GLP-1 drug: in SUSTAIN 7, semaglutide produced greater HbA1c and weight reductions than once-weekly dulaglutide [13]. So the within-class hierarchy that emerges is consistent — tirzepatide ahead of semaglutide, semaglutide ahead of dulaglutide — though each comparison rests on its own trial.
One caution about reading head-to-head numbers across these studies: the semaglutide dose differs by trial. SURPASS-2 compared tirzepatide against the 1.0 mg diabetes dose of semaglutide [9], while SURMOUNT-5 used the higher 2.4 mg obesity dose [1]. That matters because semaglutide's effect is dose-dependent, so the size of tirzepatide's lead is not a single fixed gap — it depends on which semaglutide dose sits on the other side of the comparison. The direction of the result is consistent; the magnitude is contextual.
Where semaglutide leads: hard-endpoint outcomes
Weight and HbA1c are surrogate measures. The endpoints that change lives are events — heart attacks, strokes, kidney failure, death — and here semaglutide has the published depth.
SELECT (n=17,604) showed a 20% reduction in major adverse cardiovascular events in people with cardiovascular disease and obesity but no diabetes (HR 0.80; 95% CI 0.72-0.90; P<0.001) [3]. SUSTAIN-6 showed a 26% reduction in the same composite in type 2 diabetes (HR 0.74; 95% CI 0.58-0.95) [4]. FLOW (n=3,533) showed a 24% reduction in major kidney events (HR 0.76; 95% CI 0.66-0.88) [5].
Tirzepatide's dedicated cardiovascular-outcome trial had not reported equivalent published hard-endpoint results at the time of this corpus. A 2025 modelling study projected 10-year cardiovascular-risk differences between the two agents [10], but a projection is not an outcome trial. So the honest scorecard: tirzepatide leads on the scale and on HbA1c; semaglutide leads on the breadth of proven outcomes.
Why the mechanisms differ
The reason the two drugs produce different numbers traces to what they bind. Semaglutide is a single-receptor agonist: it activates only the GLP-1 receptor, the same target as the natural incretin hormone GLP-1 [27]. Its weight effect runs mainly through appetite circuits in the brain — rodent work showed it reaches the brainstem, area postrema and hypothalamic arcuate nucleus to reduce food intake without lowering energy expenditure [6].
Tirzepatide adds a second arm: it activates the GIP receptor as well as GLP-1 (a "dual agonist"). GIP is a second incretin hormone, and engaging both pathways appears to be the mechanistic basis for the larger weight and HbA1c effects seen in the direct comparisons [1][9]. Semaglutide's counter-argument is breadth of proof rather than peak effect: its single-receptor mechanism has been carried all the way through to hard cardiovascular and kidney endpoints in SELECT, SUSTAIN-6 and FLOW [3][4][5], and to a histologic liver benefit in the 2025 ESSENCE trial [8]. Different molecular design, different shape of evidence.
How to read the trade-off
The two questions a comparison usually collapses into — "which loses more weight?" and "which is better?" — do not have the same answer here. SURMOUNT-5 settles the first in tirzepatide's favor [1]. The second depends on what you weight most: maximal weight loss, where the evidence favors tirzepatide, or the longest and broadest record of preventing cardiovascular and kidney events, where it favors semaglutide [3][5].
This digest does not adjudicate that choice — that is a clinical decision, and there is no clinician here. It lays out the figures and cites each one. For the weight evidence in depth, see semaglutide weight loss; for the mechanism behind the GIP/GLP-1 difference, see the Semaglutide research page.